Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZA47Y)

• Drug Name: Iomab-B Drug Info
• Synonyms: Iomab-B (TN)

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Bone marrow transplantation	QB63.6	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMZA47Y

Molecule-Related Drug Atlas

Drug(s) Targeting Leukocyte common antigen (PTPRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
131I-labelled aCD45	DM3YEV0	Acute myeloid leukaemia	2A60	Phase 3	[4]
[131I]-BC8	DMV86DY	leukaemia	2A60-2B33	Phase 2	[5]
LM-CD45	DMR7LKC	Transplant rejection	NE84	Phase 1	[6]
Anti-CD45 mabs	DMZ2D0G	Lymphoma	2A80-2A86	Phase 1	[7]
Iomab-ACT	DMY0QL7	B-cell acute lymphoblastic leukaemia	2B33.3	Phase 1	[8]
OX-30	DMVPG1N	Pain	MG30-MG3Z	Terminated	[9]
Asp-BrPmp-Leu	DMJEZ62	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte common antigen (PTPRC)	TTUS45N	PTPRC_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
• [4] 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91.
• [5] Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
• [7] CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
• [8] Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
• [9] CD45 / PTPRC Antibody, Biotin conjugate (OX-30).
• [10] A protected l-bromophosphonomethylphenylalanine amino acid derivative (BrPmp) for synthesis of irreversible protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2010 Dec 15;18(24):8679-86.